Marina Extends Cash Runway to Year End, Sells Off Equipment | GenomeWeb

Troubled RNAi drug firm Marina Biotech last week reported its third-quarter financial results, disclosing that a handful of money-raising deals had extended its cash runway until the end of the year.

And while the company reiterated its intention to restart its previously halted research and development operations upon the receipt of the necessary funding, its ability to do so remains unclear as it has sold “substantially all” of its equipment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.